E-viri
Recenzirano
-
O'Neil, Bert H; Cainap, Calin; Van Cutsem, Eric; Gorbunova, Vera; Karapetis, Christos S; Berlin, Jordan; Goldberg, Richard M; Qin, Qin; Qian, Jiang; Ricker, Justin L; Fischer, JuDee; McKee, Mark D; Carlson, Dawn M; Kim, Tae Won
Clinical colorectal cancer, 09/2014, Letnik: 13, Številka: 3Journal Article
Micro-Abstract In this phase II trial of 148 patients with previously treated advanced colorectal cancer (CRC), we investigated the efficacy and safety of oral linifanib (7.5 or 12.5 mg), a tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor families, or bevacizumab (10 mg/kg) in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil, folinic acid). Patients receiving linifanib did not experience a survival advantage.
